Jason Hardin
Family · Charlotte, NCNPI 1932675758
Payments from drug & device makers
Across 648 payments — averaging $57.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$19K
- Viiv Healthcare Company$13K
- Johnson & Johnson$663
- Merck$448
- AbbVie$380
- Pfizer$360
- plus $4K from 53 others
What the payments were for
- Speaking & faculty fees$19,17752%
- Travel & lodging$4,07011%
- Food & beverage$13,56137%
- Education$2491%
- Entertainment$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Biktarvy$11,940
- APRETUDE$7,714
- CABENUVA$231
- Descovy$118
- Cologuard Collection Kit$101
How this compares
$37,072 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 229 | $930,281 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 38 | $178,929 |
| CabenuvaCabotegravir/Rilpivirine | 24 | $171,022 |
| TivicayDolutegravir Sodium | 36 | $88,491 |
| JulucaDolutegravir/Rilpivirine | 26 | $86,867 |
| DovatoDolutegravir Sodium/Lamivudine | 24 | $71,052 |
| PrezcobixDarunavir/Cobicistat | 25 | $70,146 |
| DescovyEmtricitabine/Tenofov Alafenam | 21 | $51,370 |
| XifaxanRifaximin | 13 | $42,696 |
| OzempicSemaglutide | 38 | $41,104 |
| FarxigaDapagliflozin Propanediol | 41 | $34,531 |
| JardianceEmpagliflozin | 36 | $32,279 |
| EdurantRilpivirine Hcl | 18 | $28,123 |
| Nurtec OdtRimegepant Sulfate | 12 | $22,398 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $19,743 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $18,725 | $981,651250 claims |
| Viiv Healthcare CompanyCabenuva, Tivicay, Juluca, Dovato | $12,613 | $417,431110 claims |
| Janssen Products, LPSymtuza | $249 | $178,92938 claims |
| Johnson & JohnsonPrezcobix, Xarelto | $663 | $82,86240 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere | $181 | $51,90872 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $75 | $42,69613 claims |
| Novo NordiskOzempic | $147 | $41,10438 claims |
| Boehringer IngelheimJardiance, Tradjenta | $142 | $38,20548 claims |
| Janssen Scientific Affairs, LLCEdurant | $81 | $28,12318 claims |
| PfizerNurtec Odt | $360 | $22,39812 claims |
| MerckJanuvia, Janumet Xr | $448 | $21,67035 claims |
| GSKTrelegy Ellipta | $15 | $19,74331 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.
Other family in Charlotte
- Debra ScottCharlotte$129K
- Lasherri LeathersCharlotte$89K
- Catherine ShahCharlotte$72K
- Laura ListonCharlotte$33K
- Marie KristensenCharlotte$30K
- Hadley DebergCharlotte$16K
- Morgan HubeliCharlotte$15K
- Trisha WootenCharlotte$15K
- Samantha GriffinCharlotte$13K
- Leslie ByrneFayetteville$482K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.